Ask OQRO reads the filings behind this page and answers in plain words, with a link to each source.
Ask OQRO is part of OQRO Pro. Everything else on OQRO is free.
Only to see which pages are hard to use, so we can fix them. Nothing is used for ads, and what you type stays hidden (Microsoft Clarity, PostHog). Privacy Policy
Christine Fox is EVP, Head of U.S. Commercial at Teva Pharmaceutical Industries. OQRO lists 3 transactions filed with the SEC under this name, the latest on Mar 6, 2025, each linked to the official Form 4.
EVP, Head of U.S. Commercial
Disclosures on record
3
Companies involved
1
As of the latest filing on , Christine Fox reported holding 58,384 shares of Teva Pharmaceutical Industries (TEVA), worth about $2.6M at the last close of $45 (Nov 13, 2026).
| Company | Shares reported | How held | Last close | Value at last close | Reported |
|---|---|---|---|---|---|
| Teva Pharmaceutical Industries TEVA | 58,384 | 58K direct | $45 | $2.6M | Mar 5, 2025 |
Is this Christine Fox’s net worth? No. A Form 4 reports the shares an insider owns in one company after each transaction, directly or through trusts and entities. It says nothing about cash, other investments, property or debt, options not yet exercised are not counted here, and a holding reported some time ago may have changed without a new filing. The value is shares times the last stored close, not a price anyone received. Sources: the filings listed below, each linked to EDGAR. Compare with the biggest insider stakes.
Teva Pharmaceutical IndustriesTEVA
3 disclosures · Nov 2024 – Mar 2025 · 3 sold
Mar 4, 2025Sold~$63Kdisclosed Mar 6
DetailsOfficial recordMar 5, 2025Sold~$34Kdisclosed Mar 6
DetailsOfficial recordNov 20, 2024Sold~$327Kdisclosed Nov 21
DetailsOfficial recordChristine Fox has no open-market purchase on record since 2024. Sales in 2 of the 3 years since 2024.
Christine Fox reported 0 open-market purchases and 3 sales since 2024; no open-market purchase.
| Year | Bought | Sold |
|---|---|---|
| 2025 | — | $98K2×2 trades |
| 2024 | — | $327K1×1 trade |
Open-market purchases (code P) and sales (code S) on Forms 4 and 5. Up to Sep 2024 from the SEC's Insider Transactions Data Sets; since Oct 2024 from each filing as it is published. A trade filed twice (an amendment) counts once. Dollar totals use the price the filer reported; lines with no price count as trades without a value.
On the latest SEC Form 4, dated Mar 5, 2025, Christine Fox reported holding 58,384 shares of Teva Pharmaceutical Industries (TEVA). At the last close of $45 on Nov 13, 2026, that is about $2.6M. This is the stake disclosed in filings, not a net worth.
Christine Fox has no open-market purchase on record since 2024. Sales in 2 of the 3 years since 2024.
In SEC filings since 2024: no open-market purchase is on record; the latest open-market sale is from 2025.
Teva Pharmaceutical Industries (TEVA), from 2024 to 2025: 0 purchases and 3 sales.
Christine Fox reported 0 open-market purchases and 3 sales here, 2024 to 2025.
Closing prices and the companies' last annual figures; a − or + is a fact of the close, not a forecast.
